LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Ensign Reports Fiscal Year and Fourth Quarter 2023 Results; Issues 2024 Earnings Guidance

February 01, 2024 | Last Trade: US$145.68 3.11 -2.09

SAN JUAN CAPISTRANO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the fiscal and fourth quarter of 2023, reporting GAAP diluted earnings per share of $3.65 and adjusted earnings per share(1) of $4.77 for the year. Ensign also reported GAAP diluted earnings per share of $0.38 and adjusted earnings per share(1) of $1.28 for the quarter ended December 31, 2023.

Highlights Include:

  • Consolidated GAAP and adjusted revenues for the year were $3.73 billion, an increase of 23.3% over the prior year. Consolidated GAAP and adjusted revenues for the quarter were $980.4 million, an increase of 21.1% over the prior year quarter.
     
  • GAAP diluted earnings per share was $3.65 or the year and $0.38 for the quarter, both of which include the impact of certain litigation matters arising outside the ordinary course of business.
     
  • Adjusted diluted earnings per share(1) was $4.77 for the year and $1.28 for the quarter, an increase of 15.2% and 16.4% over the prior year and prior year quarter, respectively.
     
  • GAAP net income was $209.4 million for the year and $21.7 for the quarter, both of which includes the impact of certain litigation matters arising outside the ordinary course of business.
     
  • Adjusted net income(1) was $273.5 million for the year and $73.7 million for the quarter, an increase of 16.0% and 17.5% over the prior year and prior year quarter, respectively.
     
  • Same store and transitioning occupancy both increased by 3.2% over the prior year and increased by 2.4% and 1.5%, respectively, over the prior year quarter.
     
  • Total skilled services(2) revenue was $3.58 billion for the year, an increase of 23.1% over the prior year, and was $940.8 million for the quarter, an increase of 21.0% over the prior year quarter.
     
  • Same store and transitioning combined managed care revenue increased by 12.3% and managed care census increased by 3.5%, both over the prior year quarter.
     
  • Standard Bearer(2) revenue was $82.5 million for the year, an increase of 13.1% from the prior year, and $21.9 million for the quarter, an increase of 12.7% from the prior year quarter. FFO was $54.3 million for the year, an increase of 9.7% from the prior year, and $14.2 million for the quarter, an increase of 9.4% from the prior year quarter.

(1) See "Reconciliation of GAAP to Non-GAAP Financial Information". 
(2) Our Skilled Services and Standard Bearer Segments are defined and outlined in Note 8 of Item 8. Financial Statements and Supplementary Data on Form 10-K.

Operating Results

“Our local teams have once again posted impressive clinical and financial results and continue to build remarkable momentum in each market across our portfolio,” said Barry Port, Ensign’s Chief Executive Officer. “We were pleased to see same store occupancy of 79.9%, which grew by 240 basis points over the prior year quarter. In addition, we saw an improvement in occupancy on a sequential basis of 40 basis points over the third quarter. As expected, we also saw an increase in our skilled mix during the quarter as our same store days for the quarter increased by 110 basis points sequentially over the third quarter. Our success is entirely due to the efforts and commitment of those leadership teams, caregivers, field resources and service center partners. After another record quarter, we are excited about the many opportunities to continue to capture the enormous potential inherent in our portfolio as we relentlessly focus on our operational fundamentals, both in existing operations and the growing number of new acquisitions,” Port added.

“We are very humbled by what we were able to accomplish in 2023, but we are eager to continue to drive improvements in our existing portfolio and to take advantage of the acquisition opportunities that we see on the horizon. We are issuing our annual 2024 earnings guidance of $5.29 to $5.47 per diluted share and annual revenue guidance of $4.13 billion to $4.17 billion. The midpoint of this 2024 earnings guidance represents an increase of 13% over our 2023 results and is 30% higher than our 2022 results. When we consider the current health of our organization, combined with our culture and proven local leadership strategy, we are well-positioned to have another outstanding year in 2024," Port said.

Chad Keetch, Ensign’s Chief Investment Officer and Executive Vice President noted the progress the Company is making with its newly acquired operations. He said, “As we expected, we continued to add to our growing portfolio and are very excited about the three new operations and one real estate asset we added during the quarter and since, bringing the number of operations acquired since 2022 to 54. Looking closer at these new operations, occupancy and skilled mix days for the skilled nursing operations in the recently acquired bucket were 77.6% and 27.5%, respectively, for the quarter. When compared to our same store occupancy and skilled mix days of 79.9% and 30.9%, respectively, there is enormous upside in each of these new operations as they continue to transform into ‘same store’ caliber operations.”

Speaking to the Company’s financial health, Suzanne Snapper, Ensign’s Executive Vice President and Chief Financial Officer reported that the Company’s liquidity remains strong with approximately $509.6 million of cash on hand and $593.7 million of available capacity under its line-of-credit. Ms. Snapper also indicated that, “Management’s guidance is based on diluted weighted average common shares outstanding of approximately 58.5 million and a 25.0% tax rate. In addition, the guidance assumes, among other things, normalized health insurance costs and management’s current expectations regarding reimbursement rates. It also excludes one-time charges, including certain expenses related to litigation matters arising outside of the ordinary course of business, acquisition-related costs and amortization costs related to intangible assets acquired and share-based compensation.”

A discussion of the Company's use of non-GAAP financial measures is set forth below. A reconciliation of net income to adjusted EBT, EBITDA, adjusted EBITDAR, adjusted EBITDA and FFO for Standard Bearer, as well as, a reconciliation of GAAP earnings per share, net income to adjusted net income and adjusted net earnings per share appear in the financial data portion of this release. More complete information is contained in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, which is expected to be filed with the SEC today and can be viewed on the Company’s website at http://www.ensigngroup.net.

Growth and Real Estate Highlights

Mr. Keetch added additional commentary on the Company’s continued acquisition activity. “The pipeline for new deals remains strong. We are lining up several exciting opportunities and expect to announce several deals over the coming months. We remain poised to grow with over a billion dollars in dry powder for future investments and our local leaders continue to recruit future CEOs of Ensign affiliated operations. We currently have a deep bench of CEO’s-in-training that are eagerly preparing for their opportunity to lead. We continue to see evidence that many operators in this industry are struggling, and we expect that the operating environment will translate into many near and long-term opportunities to both lease and acquire post-acute care assets. However, as we’ve said before, we do not set arbitrary growth goals and will remain true to our disciplined acquisition strategy, only growing when we have the right leaders in place and the pricing is right.”

The recent acquisitions include the following operations:

  • Providence Place, a 45-bed skilled nursing facility located in Kansas City, Kansas;

  • Hearthstone Health and Rehabilitation, a 125-bed skilled nursing facility located in Sparks, Nevada;

  • TriState Health and Rehabilitation Center, a 116-bed skilled nursing facility located in Harrogate, Tennessee; and

  • Champions Healthcare at Willowbrook, a healthcare campus consisting of a 98-bed skilled nursing facility and a 144-bed assisted living facility located in Houston, Texas, which included the real estate assets that were acquired by Standard Bearer.

Ensign's growing portfolio consists of 299 healthcare operations, 27 of which also include senior living operations, across 14 states. Ensign now owns 113 real estate assets, 83 of which it operates. Keetch noted that Ensign’s overall strategy will continue to include both leasing and acquiring real estate and that the Company is actively looking for performing and underperforming operations in several states.

The Company continues to provide additional disclosures on Standard Bearer, which is comprised of 108 properties owned by the Company and leased to 79 affiliated skilled nursing and senior living operations and 30 operations that are leased to third party operators (numbers reflect one shared campus that is jointly used by the Company and a third party operator). Keetch noted that each of these properties are subject to triple-net, long-term leases and generated rental revenue of $21.9 million for the quarter, of which $17.7 million was derived from Ensign affiliated operations. For the quarter, Ensign reported $14.2 million in FFO.

The Company paid a quarterly cash dividend of $0.06 per share of Ensign common stock. Ms. Snapper noted that the Company’s liquidity remains strong and that the Company plans to continue its long history of paying dividends into the future, noting that in December of 2023 the Company increased the annual dividend for the 21st consecutive year.

Conference Call

A live webcast will be held Friday, February 2, 2024 at 10:00 a.m. Pacific time (1:00 p.m. Eastern time) to discuss Ensign’s fourth quarter and fiscal year of 2023 financial results. To listen to the webcast, or to view any financial or statistical information required by SEC Regulation G, please visit the Investors Relations section of Ensign’s website at http://investor.ensigngroup.net. The webcast will be recorded and will be available for replay via the website until 5:00 p.m. Pacific time on Friday, March 1, 2024.

About Ensign™

The Ensign Group, Inc.'s independent subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 299 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. As part of its investment strategy, the Company will also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. Ensign’s new business venture operating subsidiaries also offer several other post-acute-related services, including mobile x-ray, non-emergency transportation services, long-term care pharmacy and other consulting services also across several states. Each of these operations is operated by a separate, independent subsidiary that has its own management, employees and assets. References herein to the consolidated "Company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the facilities, the Service Center, Standard Bearer or the captive insurance subsidiary are operated by the same entity. More information about Ensign is available at http://www.ensigngroup.net.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains, and the related conference call and webcast will include, forward-looking statements that are based on management’s current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding growth prospects, future operating and financial performance, and acquisition activities. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.

These risks and uncertainties relate to the Company’s business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve operations, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of operations; its ability to access capital on a cost-effective basis to continue to successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of operations; competition from other companies in the acquisition, development and operation of facilities; its ability to defend claims and lawsuits, including professional liability claims alleging that our services resulted in personal injury, and other regulatory-related claims; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its operations if necessary. Additionally, our business and operations continue to be impacted by the unprecedented nature of the changes in the regulations and environment, as such, we are unable to predict the full extent and duration of the financial impact of these changes on our business, financial condition and results of operations. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company’s periodic filings with the Securities and Exchange Commission, including its Form 10-Q and 10-K, for a more complete discussion of the risks and other factors that could affect Ensign’s business, prospects and any forward-looking statements. Except as required by the federal securities laws, Ensign does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.

Contact Information

Investor/Media Relations, The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it..

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF INCOME
 
 Three Months Ended December 31, Year Ended December 31,
  2023   2022   2023   2022 
        
 (In thousands, except per share data)
REVENUE       
Service revenue$974,728  $805,325  $3,708,071  $3,008,711 
Rental revenue 5,650   4,207   21,284   16,757 
TOTAL REVENUE$980,378  $809,532  $3,729,355  $3,025,468 
Expense:       
Cost of services 781,158   633,529   2,941,238   2,354,434 
Rent—cost of services 50,604   41,152   197,358   153,049 
General and administrative expense 106,557   42,775   263,005   158,805 
Depreciation and amortization 19,233   16,880   72,387   62,355 
TOTAL EXPENSES$957,552  $734,336  $3,473,988  $2,728,643 
Income from operations 22,826   75,196   255,367   296,825 
Other income (expense):       
Interest expense (2,004)  (2,067)  (8,087)  (8,931)
Other income 10,460   4,322   25,482   1,195 
Other income (expense), net$8,456  $2,255  $17,395  $(7,736)
Income before provision for income taxes 31,282   77,451   272,762   289,089 
Provision for income taxes 9,459   16,932   62,912   64,437 
NET INCOME$21,823  $60,519  $209,850  $224,652 
Less: net income (loss) attributable to noncontrolling interests 132   48   451   (29)
Net income attributable to The Ensign Group, Inc.$21,691  $60,471  $209,399  $224,681 
        
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.       
Basic$0.39  $1.10  $3.76  $4.09 
Diluted$0.38  $1.06  $3.65  $3.95 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING       
Basic 56,083   55,087   55,708   54,887 
Diluted 57,555   56,973   57,323   56,871 

 

THE ENSIGN GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands)
 
 December 31,
  2023  2022
    
ASSETS   
Current assets:   
Cash and cash equivalents$509,626 $316,270
Accounts receivable—less allowance for doubtful accounts of $9,348 and $7,802 at December 31, 2023 and 2022, respectively 485,039  408,432
Investments—current 17,229  15,441
Prepaid expenses and other current assets 35,036  40,982
Total current assets 1,046,930  781,125
Property and equipment, net 1,090,771  992,010
Right-of-use assets 1,756,430  1,450,995
Insurance subsidiary deposits and investments 92,687  67,652
Deferred tax assets 67,124  39,643
Restricted and other assets 40,205  37,291
Intangible assets, net 6,525  6,437
Goodwill 76,869  76,869
TOTAL ASSETS$4,177,541 $3,452,022
LIABILITIES AND EQUITY   
Current liabilities:   
Accounts payable$92,811 $77,087
Accrued wages and related liabilities 332,568  289,810
Lease liabilities—current 82,526  65,796
Accrued self-insurance liabilities—current 54,664  48,187
Other accrued liabilities 168,228  97,309
Current maturities of long-term debt 3,950  3,883
Total current liabilities 734,747  582,072
Long-term debt—less current maturities 145,497  149,269
Long-term lease liabilities—less current portion 1,639,326  1,355,113
Accrued self-insurance liabilities—less current portion 111,246  83,495
Other long-term liabilities 49,408  33,273
Total equity 1,497,317  1,248,800
TOTAL LIABILITIES AND EQUITY$4,177,541 $3,452,022

THE ENSIGN GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

The following table presents selected data from our consolidated statements of cash flows for the periods presented:

 Year Ended December 31,
  2023   2022 
    
NET CASH PROVIDED BY/(USED IN):(In thousands)
Operating activities$376,666  $272,513 
Investing activities (182,698)  (186,182)
Financing activities (612)  (32,262)
Net increase in cash and cash equivalents 193,356   54,069 
Cash and cash equivalents beginning of period 316,270   262,201 
Cash and cash equivalents at end of period$509,626  $316,270 

THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands, except per share data)

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME

The following table reconciles GAAP net income to Non-GAAP net income for the periods presented:

 Three Months Ended December 31, Year Ended December 31,
  2023   2022   2023   2022 
Net income attributable to The Ensign Group, Inc.$21,691  $60,471  $209,399  $224,681 
Non-GAAP adjustments       
Stock-based compensation expense(a) 8,076   6,039   30,767   22,720 
Litigation(b) 58,816   68   60,781   4,280 
Cost of services - gain on sale of assets and business interruption recoveries (123)  (913)  (1,132)  (4,380)
Cost of services - acquisition related costs(c) 92   253   814   669 
Interest expense - write-off of deferred financing fees(d)          566 
General and administrative - costs incurred related to new systems implementation 88   682   963   1,072 
Depreciation and amortization - patient base(e) 173   107   355   320 
Provision for income taxes on Non-GAAP adjustments(f) (15,142)  (3,990)  (28,416)  (14,215)
Non-GAAP Net Income$73,671  $62,717  $273,531  $235,713 
        
Average number of diluted shares outstanding 57,555   56,973   57,323   56,871 
        
Diluted Earnings Per Share       
Net Income$0.38  $1.06  $3.65  $3.95 
        
Adjusted Diluted Earnings Per Share       
Net Income$1.28  $1.10  $4.77  $4.14 
        
Footnotes:       
(a) Represents stock-based compensation expense incurred.    
 Three Months Ended December 31, Year Ended December 31,
  2023   2022   2023   2022 
Cost of services$5,351  $3,959  $20,622  $14,897 
General and administrative 2,725   2,080   10,145   7,823 
Total Non-GAAP adjustment$8,076  $6,039  $30,767  $22,720 
        
(b) Litigation relates to specific proceedings arising outside of the ordinary course of business, which excludes the portion attributable to non-controlling interests.
 Three Months Ended December 31, Year Ended December 31,
  2023   2022   2023   2022 
Cost of services$4,600  $68  $3,782  $4,280 
General and administrative 54,216      56,999    
Total Non-GAAP adjustment$58,816  $68  $60,781  $4,280 
        
(c) Represents costs incurred to acquire operations that are not capitalizable.
(d) Represents the write-off of deferred financing fees associated with the amendment of the Credit Facility.
(e) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.
(f) Represents an adjustment to the provision for income tax to our historical year to date effective tax rate of 25.0%.

THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

 Three Months Ended December 31, Year Ended December 31,
  2023   2022   2023   2022 
Consolidated Statements of Income Data:       
Net income$21,823  $60,519  $209,850  $224,652 
Less: net income (loss) attributable to noncontrolling interests 132   48   451   (29)
Add: Other (income) expense, net (8,456)  (2,255)  (17,395)  7,736 
Provision for income taxes 9,459   16,932   62,912   64,437 
Depreciation and amortization 19,233   16,880   72,387   62,355 
EBITDA$41,927  $92,028  $327,303  $359,209 
Adjustments to EBITDA:       
Stock-based compensation expense 8,076   6,039   30,767   22,720 
Litigation(a) 58,816   68   60,781   4,280 
Gain on sale of assets and business interruption recoveries (123)  (913)  (1,132)  (4,380)
Acquisition related costs(b) 92   253   814   669 
Costs incurred related to new systems implementation 88   682   963   1,072 
ADJUSTED EBITDA$108,876  $98,157  $419,496  $383,570 
Rent—cost of services 50,604   41,152   197,358   153,049 
ADJUSTED EBITDAR$159,480    $616,854   
        

(a) Litigation relates to specific proceedings arising outside of the ordinary course of business, which excludes the portion attributable to non-controlling interests.
(b) Costs incurred to acquire operations that are not capitalizable.

THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)

The table below reconciles income before provision for income taxes to Adjusted EBT for the periods presented:

 Three Months Ended December 31, Year Ended December 31,
  2023   2022   2023   2022 
        
ConsolidatedStatements of Income Data:(In thousands)
Income before provision for income taxes$31,282  $77,451  $272,762  $289,089 
Stock-based compensation expense 8,076   6,039   30,767   22,720 
Litigation(a) 58,816   68   60,781   4,553 
Gain on sale of assets and business interruption recoveries (123)  (913)  (1,132)  (4,380)
Write-off of deferred financing fees(b)          566 
Acquisition related costs(c) 92   253   814   669 
Costs incurred related to new systems implementation 88   682   963   1,072 
Depreciation and amortization - patient base(d) 173   107   355   320 
ADJUSTED EBT$98,404  $83,687  $365,310  $314,609 

(a) Litigation relates to specific proceedings arising outside of the ordinary course of business, which includes the portion attributable to non-controlling interests.
(b) Represents the write-off of deferred financing fees associated with the amendment of the Credit Facility.
(c) Costs incurred to acquire operations that are not capitalizable.
(d) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.

 

THE ENSIGN GROUP, INC.
UNAUDITED SELECT PERFORMANCE INDICATORS

The following tables summarize our selected performance indicators for our skilled services segment along with other statistics, for each of the dates or periods presented:

 Three Months Ended December 31,
  2023   2022  Change % Change
        
TOTAL FACILITY RESULTS:(Dollars in thousands)
Skilled services revenue$940,765  $777,648  $163,117 21.0%
Number of facilities at period end 259   234   25 10.7%
Number of campuses at period end(1) 27   26   1 3.8%
Actual patient days 2,227,888   1,956,091   271,797 13.9%
Occupancy percentage — Operational beds 79.2%  76.2%   3.0%
Skilled mix by nursing days 29.5%  30.9%   (1.4)%
Skilled mix by nursing revenue 49.0%  51.1%   (2.1)%

 

 Three Months Ended December 31,
  2023   2022  Change % Change
        
SAME FACILITY RESULTS:(2)(Dollars in thousands)
Skilled services revenue$713,342  $660,420  $52,922 8.0%
Number of facilities at period end 189   189    %
Number of campuses at period end(1) 24   24    %
Actual patient days 1,668,368   1,619,163   49,205 3.0%
Occupancy percentage — Operational beds 79.9%  77.5%   2.4%
Skilled mix by nursing days 30.9%  32.7%   (1.8)%
Skilled mix by nursing revenue 50.3%  53.0%   (2.7)%

 

 Three Months Ended December 31,
  2023   2022  Change % Change
        
TRANSITIONING FACILITY RESULTS:(3)(Dollars in thousands)
Skilled services revenue$64,924  $59,672  $5,252 8.8%
Number of facilities at period end 22   22    %
Number of campuses at period end(1) 1   1    %
Actual patient days 166,349   162,237   4,112 2.5%
Occupancy percentage — Operational beds 76.5%  75.0%   1.5%
Skilled mix by nursing days 20.4%  22.4%   (2.0)%
Skilled mix by nursing revenue 37.4%  40.1%   (2.7)%

 

 Three Months Ended December 31,
  2023   2022  Change % Change
        
RECENTLY ACQUIRED FACILITY RESULTS:(4)(Dollars in thousands)
Skilled services revenue$162,499  $57,556  $104,943 NM
Number of facilities at period end 48   23   25 NM
Number of campuses at period end(1) 2   1   1 NM
Actual patient days 393,171   174,691   218,480 NM
Occupancy percentage — Operational beds 77.6%  66.9%   NM
Skilled mix by nursing days 27.5%  21.3%   NM
Skilled mix by nursing revenue 48.3%  40.3%   NM

(1) Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.
(2) Same Facility results represent all facilities purchased prior to January 1, 2020.
(3) Transitioning Facility results represent all facilities purchased from January 1, 2020 to December 31, 2021.
(4) Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2022.

 Year Ended December 31,
  2023   2022  Change % Change
        
TOTAL FACILITY RESULTS:(Dollars in thousands)
Skilled services revenue$3,578,855  $2,906,215  $672,640 23.1%
Number of facilities at period end 259   234   25 10.7%
Number of campuses at period end(1) 27   26   1 3.8%
Actual patient days 8,590,995   7,243,781   1,347,214 18.6%
Occupancy percentage — Operational beds 78.5%  75.3%   3.2%
Skilled mix by nursing days 30.4%  31.8%   (1.4)%
Skilled mix by nursing revenue 50.2%  52.0%   (1.8)%

 

 Year Ended December 31,
  2023   2022  Change % Change
        
SAME FACILITY RESULTS:(2)(Dollars in thousands)
Skilled services revenue$2,771,633  $2,569,807  $201,826 7.9%
Number of facilities at period end 189   189    %
Number of campuses at period end(1) 24   24    %
Actual patient days 6,563,672   6,299,331   264,341 4.2%
Occupancy percentage — Operational beds 79.2%  76.0%   3.2%
Skilled mix by nursing days 31.9%  33.0%   (1.1)%
Skilled mix by nursing revenue 51.4%  53.3%   (1.9)%

 

 Year Ended December 31,
  2023   2022  Change % Change
        
TRANSITIONING FACILITY RESULTS:(3)(Dollars in thousands)
Skilled services revenue$251,872  $231,100  $20,772 9.0%
Number of facilities at period end 22   22    %
Number of campuses at period end(1) 1   1    %
Actual patient days 655,659   625,085   30,574 4.9%
Occupancy percentage — Operational beds 76.1%  72.9%   3.2%
Skilled mix by nursing days 21.4%  23.1%   (1.7)%
Skilled mix by nursing revenue 38.5%  41.4%   (2.9)%

 

 Year Ended December 31,
  2023   2022  Change % Change
        
RECENTLY ACQUIRED FACILITY RESULTS:(4)(Dollars in thousands)
Skilled services revenue$555,350  $105,308  $450,042 NM
Number of facilities at period end 48   23   25 NM
Number of campuses at period end(1) 2   1   1 NM
Actual patient days 1,371,664   319,365   1,052,299 NM
Occupancy percentage — Operational beds 76.8%  67.9%   NM
Skilled mix by nursing days 27.5%  24.3%   NM
Skilled mix by nursing revenue 49.3%  42.8%   NM

(1) Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.
(2) Same Facility results represent all facilities purchased prior to January 1, 2020.
(3) Transitioning Facility results represent all facilities purchased from January 1, 2020 to December 31, 2021.
(4) Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2022.

THE ENSIGN GROUP, INC.
SKILLED NURSING AVERAGE DAILY REVENUE RATES AND
PERCENT OF SKILLED NURSING REVENUE AND DAYS BY PAYOR
(Unaudited)

The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate(1):

 Three Months Ended December 31,
 Same Facility Transitioning Acquisitions Total
  2023  2022  2023  2022  2023  2022  2023  2022
                
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare$746.68 $707.77 $722.56 $674.10 $818.63 $638.98 $760.57 $700.23
Managed care 556.84  513.04  565.95  528.38  572.76  468.44  559.23  511.90
Other skilled 608.23  593.50  547.36  516.52  384.50  433.23  571.93  578.36
Total skilled revenue 633.89  605.95  638.68  605.32  665.51  545.94  639.33  602.22
Medicaid 283.87  263.11  277.73  263.75  270.16  221.30  280.85  258.91
Private and other payors 265.72  253.50  251.38  246.51  271.20  207.31  265.52  248.24
Total skilled nursing revenue$390.10 $374.35 $347.93 $338.50 $378.93 $288.74 $384.97 $363.73

(1) These rates exclude state relief funding.

 Year Ended December 31,
 Same Facility Transitioning Acquisitions Total
  2023  2022  2023  2022  2023  2022  2023  2022
                
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare$722.96 $694.63 $696.37 $668.05 $788.00 $652.15 $733.47 $691.25
Managed care 537.29  510.18  536.93  501.73  555.55  455.19  539.25  508.53
Other skilled 598.35  576.46  529.08  530.18  441.89  429.84  575.34  563.56
Total skilled revenue 617.55  598.14  615.58  593.66  660.87  521.24  623.70  595.26
Medicaid 275.82  259.89  270.67  254.08  256.51  227.21  272.14  257.67
Private and other payors 263.81  250.80  253.15  248.63  263.71  199.34  262.93  248.54
Total skilled nursing revenue$383.56 $370.57 $342.57 $332.09 $368.46 $296.15 $378.02 $363.97

(1) These rates exclude state relief funding and include sequestration reversal of 1% for the second quarter in 2022 and 2% for the first quarter of 2022.

The following tables set forth our percentage of skilled nursing patient revenue and days by payor source for the periods presented:

 Three Months Ended December 31,
 Same Facility Transitioning Acquisitions Total
 2023  2022  2023  2022  2023  2022  2023  2022 
                
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare21.0% 25.4% 20.4% 23.9% 30.0% 23.4% 22.5% 25.1%
Managed care20.2  19.2  12.3  13.2  13.7  10.3  18.6  18.1 
Other skilled9.1  8.4  4.7  3.0  4.6  6.6  7.9  7.9 
Skilled mix50.3  53.0  37.4  40.1  48.3  40.3  49.0  51.1 
Private and other payors7.6  7.0  8.9  7.9  8.2  8.6  7.9  7.2 
Medicaid42.1  40.0  53.7  52.0  43.5  51.1  43.1  41.7 
TOTAL SKILLED NURSING100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

 

 Three Months Ended December 31,
 Same Facility Transitioning Acquisitions Total
 2023  2022  2023  2022  2023  2022  2023  2022 
                
PERCENTAGE OF SKILLED NURSING DAYS
Medicare11.0% 13.4% 9.8% 12.0% 13.9% 10.6% 11.4% 13.1%
Managed care14.2  14.0  7.6  8.5  9.0  6.4  12.8  12.9 
Other skilled5.7  5.3  3.0  1.9  4.6  4.3  5.3  4.9 
Skilled mix30.9  32.7  20.4  22.4  27.5  21.3  29.5  30.9 
Private and other payors11.3  10.5  12.4  10.8  11.4  12.0  11.4  10.5 
Medicaid57.8  56.8  67.2  66.8  61.1  66.7  59.1  58.6 
TOTAL SKILLED NURSING100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

 

 Year Ended December 31,
 Same Facility Transitioning Acquisitions Total
 2023  2022  2023  2022  2023  2022  2023  2022 
                
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare22.5% 26.0% 21.8% 24.9% 31.0% 20.4% 23.8% 25.7%
Managed care20.1  19.2  12.6  12.6  13.3  9.9  18.5  18.3 
Other skilled8.8  8.1  4.1  3.9  5.0  12.5  7.9  8.0 
Skilled mix51.4  53.3  38.5  41.4  49.3  42.8  50.2  52.0 
Private and other payors7.5  7.0  8.6  8.1  8.0  6.4  7.6  7.0 
Medicaid41.1  39.7  52.9  50.5  42.7  50.8  42.2  41.0 
TOTAL SKILLED NURSING100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

 

 Year Ended December 31,
 Same Facility Transitioning Acquisitions Total
 2023  2022  2023  2022  2023  2022  2023  2022 
                
PERCENTAGE OF SKILLED NURSING DAYS
Medicare11.9% 13.9% 10.7% 12.4% 14.5% 9.3% 12.3% 13.5%
Managed care14.4  14.0  8.0  8.3  8.8  6.4  13.0  13.1 
Other skilled5.6  5.1  2.7  2.4  4.2  8.6  5.1  5.2 
Skilled mix31.9  33.0  21.4  23.1  27.5  24.3  30.4  31.8 
Private and other payors11.0  10.4  11.7  10.8  11.1  9.5  11.0  10.3 
Medicaid57.1  56.6  66.9  66.1  61.4  66.2  58.6  57.9 
TOTAL SKILLED NURSING100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

THE ENSIGN GROUP, INC.
UNAUDITED REVENUE BY PAYOR SOURCE

The following table sets forth our service revenue by payor source and as a percentage of total service revenue for the periods presented:

 Three Months Ended December 31,
  2023   2022 
 Revenue % of Revenue Revenue % of Revenue
Medicaid(1)$384,566 39.5% $320,065 39.7%
Medicare 252,414 25.9   222,151 27.6 
Medicaid — skilled 63,269 6.4   54,523 6.8 
Total Medicaid and Medicare 700,249 71.8   596,739 74.1 
Managed care 177,618 18.2   136,674 17.0 
Private and other(2) 96,861 10.0   71,912 8.9 
SERVICE REVENUE$974,728 100.0% $805,325 100.0%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Year Ended December 31,
  2023   2022 
 Revenue % of Revenue Revenue % of Revenue
Medicaid(1)$1,459,449 39.4% $1,183,156 39.3%
Medicare 985,749 26.6   832,160 27.7 
Medicaid — skilled 245,663 6.6   200,878 6.7 
Total Medicaid and Medicare 2,690,861 72.6   2,216,194 73.7 
Managed care 666,129 18.0   525,710 17.5 
Private and other(2) 351,081 9.4   266,807 8.8 
SERVICE REVENUE$3,708,071 100.0% $3,008,711 100.0%

(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION BY SEGMENT
(In thousands)

Skilled Services

The table below reconciles net income to EBITDA and Adjusted EBITDA for the skilled services reportable segment for the periods presented:

 Three Months Ended December 31, Year Ended December 31,
  2023  2022   2023   2022 
Statements of Income Data:       
Segment income(a)$116,756 $106,460  $464,925  $408,732 
Depreciation and amortization 10,349  8,813   38,766   33,224 
EBITDA$127,105 $115,273  $503,691  $441,956 
Adjustments to EBITDA:       
Business interruption recoveries   (913)  (1,009)  (913)
Stock-based compensation expense 5,164  3,823   19,904   14,394 
Litigation(b) 4,600     4,600    
ADJUSTED EBITDA$136,869 $118,183  $527,186  $455,437 
        

(a) Segment income reflects profit or loss from operations before provision for income taxes and impairment charges from operations. General and administrative expenses are not allocated to the skilled services segment for purposes of determining segment profit or loss.
(b) Litigation relates to specific proceedings arising outside of the ordinary course of business.

Standard Bearer

The following table sets forth details of operating results for our revenue and earnings, and their respective components, by Standard Bearer for the periods presented:

 Three Months Ended December 31, Year Ended December 31,
  2023  2022  2023  2022
        
Rental revenue generated from third-party tenants$4,198 $3,790 $15,774 $14,970
Rental revenue generated from Ensign independent subsidiaries 17,677  15,624  66,712  57,967
TOTAL RENTAL REVENUE$21,875 $19,414 $82,486 $72,937
Segment income(a) 7,548  7,192  29,065  27,871
Depreciation and amortization 6,677  5,815  25,205  21,613
FFO(b)$14,225 $13,007 $54,270 $49,484
        

(a) Segment income reflects profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate and insurance recoveries and charges from real estate. Included in Standard Bearer expenses for the quarter and year ended December 31, 2023 is the management fee of $1.3 million and $5.0 million, respectively, and interest of $3.8 million and $12.9 million, respectively, from intercompany agreements between Standard Bearer and the Company and its independent subsidiaries, including the Service Center. Included in Standard Bearer expenses for the quarter and year ended December 31, 2022 is the management fee of $1.2 million and $4.4 million, respectively, and interest of $2.5 million and $8.6 million, respectively, from intercompany agreements between Standard Bearer and the Company and its independent subsidiaries, including the Service Center.

(b) FFO, in accordance with the definition used by the National Association of Real Estate Investment Trusts, means net income attributable to common stockholders, computed in accordance with U.S. GAAP, excluding gains or losses from sales of real estate and impairment of depreciable real estate assets, while including depreciation and amortization related to real estate to earnings.

Discussion of Non-GAAP Financial Measures

EBITDA consists of net income before (a) other (income) expense, net, (b) provisions for income taxes and (c) depreciation and amortization. Adjusted EBITDA consists of net income before (a) other (income) expense, net, (b) provisions for income taxes, (c) depreciation and amortization, (d) stock-based compensation expense, (e) acquisition related costs, (f) costs incurred related to new systems implementation, (g) litigation and (h) gain on sale of assets and business interruption recoveries. Adjusted EBITDAR consists of net income before (a) other (income) expense, net, (b) provisions for income taxes, (c) depreciation and amortization, (d) rent-cost of services, (e) stock-based compensation expense, (f) acquisition related costs, (g) costs incurred related to new systems implementation, (h) litigation and (i) gain on sale of assets and business interruption recoveries. Adjusted EBT consists of (a) income before provision for income taxes, (b) stock-based compensation expense, (c) acquisition related costs, (d) costs incurred related to new systems implementation, (e) litigation, (f) gain on sale of assets and business interruption recoveries, (g) write-off of deferred financing fees and (h) depreciation and amortization of patient base intangible assets. Funds from Operations (FFO) for our Standard Bearer segment consists of segment income, excluding depreciation and amortization related to real estate. The Company believes that the presentation of adjusted net income, adjusted earnings per share, EBITDA, adjusted EBITDA, adjusted EBT and FFO provides important supplemental information to management and investors to evaluate the Company’s operating performance. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense. The Company believes disclosure of adjusted net income, adjusted net income per share, EBITDA, adjusted EBITDA, adjusted EBITDAR, adjusted EBT and FFO has substance because the excluded revenues and expenses are infrequent in nature and are variable in nature, or do not represent current revenues or cash expenditures. A material limitation associated with the use of these measures as compared to the GAAP measures of net income and diluted earnings per share is that they may not be comparable with the calculation of net income and diluted earnings per share for other companies in the Company's industry. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. For further information regarding why the Company believes that this non-GAAP measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company’s periodic filings are available on the SEC's website at www.sec.gov or under the "Financials" link of the Investor Relations section on Ensign’s website at http://www.ensigngroup.net

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB